| Literature DB >> 32155852 |
Jadwiga Jodynis-Liebert1, Małgorzata Kujawska1.
Abstract
Many phytochemicals demonstrate nonmonotonic dose/concentration-response termed biphasic dose-response and are considered to be hormetic compounds, i.e., they induce biologically opposite effects at different doses. In numerous articles the hormetic nature of phytochemicals is declared, however, no experimental evidence is provided. Our aim was to present the overview of the reports in which phytochemical-induced biphasic dose-response is experimentally proven. Hence, we included in the current review only articles in which the reversal of response between low and high doses/concentrations of phytochemicals for a single endpoint was documented. The majority of data on biphasic dose-response have been found for phytoestrogens; other reports described these types of effects for resveratrol, sulforaphane, and natural compounds from various chemical classes such as isoquinoline alkaloid berberine, polyacetylenes falcarinol and falcarindiol, prenylated pterocarpan glyceollin1, naphthoquinones plumbagin and naphazarin, and panaxatriol saponins. The prevailing part of the studies presented in the current review was performed on cell cultures. The most common endpoint tested was a proliferation of tumor and non-cancerous cells. Very few experiments demonstrating biphasic dose-response induced by phytochemicals were carried out on animal models. Data on the biphasic dose-response of various endpoints to phytochemicals may have a potential therapeutic or preventive implication.Entities:
Keywords: cancer; diet; flavonoids; food supplements; hormesis; phytoestrogens; resveratrol; sulforaphane
Year: 2020 PMID: 32155852 PMCID: PMC7141213 DOI: 10.3390/jcm9030718
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Phytoestrogens displaying biphasic concentration-response relationship.
| Compound * | Model | Concentration | Effects | Mechanism | Refs |
|---|---|---|---|---|---|
|
| |||||
| Artelastin Artelastocarpin Artelastochromen Carpelastofuran | MCF-7 | 0.02–2.90 μM | ↑proliferation, DNA synthesis | [ | |
| >3.12 μM | ↓proliferation | ||||
| 25 μM | ↓DNA synthesis | ||||
| Biochanin A | MCF-7 | ~4–35 μM | ↑proliferation | [ | |
| ~106–352 μM | ↓proliferation | ||||
| ~18 μM | ↑DNA synthesis | ||||
| ~70 μM | ↓DNA synthesis | ||||
| T-47D | ~4 μM | ↑proliferation | ↓p53 | [ | |
| ~70 μM | ↓proliferation | ↑p53 | |||
| Breviflavone B | MCF-7 | 450 nM | ↑proliferation | [ | |
| 2.2–6.6 μM | ↓proliferation | ↓ERα | |||
| Daidzein | T-47D | ~1–79 μM | ↑proliferation | ↓p53 | [ |
| ~157 μM | ↓proliferation | ↑p53 | |||
| MCF-7 | ~1 μM | ↑proliferation | [ | ||
| >10 μM | ↓proliferation | ||||
| LoVo | 0.1, 1.0 μM | ↑proliferation | [ | ||
| 10–100 μM | ↓proliferation | G0/G1 arrest | |||
| ↑caspase-3 | |||||
| KS483, mouse bone marrow cells | <20 μM | ↑osteogenesis ↓adipogenesis | PPARs transactivation | [ | |
| >30 μM | ↓osteogenesis ↑adipogenesis | ||||
| Enterodiol Enterolactone | MG-63 | ~33 μM | ↑viability | ↑ | [ |
| ~33–333 μM | ↑ALP activity | ||||
| >333 μM | ↓viability | ↓ | |||
| ~3–33 mM | ↓ALP activity | ||||
| Genistein | MCF-7 | <1 μM | ↑proliferation | ↑ER transcription | [ |
| >10 μM | ↓proliferation | ||||
| PC-3 | 500–1000 nM | ↑proliferation, | ↑MMP-9 activity | [ | |
| ↑osteopontin | |||||
| 50,000 nM | ↓proliferation | ↓MMP-9 activity | |||
| RWPE-1 | 1.5–12.5 μM | ↑proliferation | ↑ERK1/2 activity | [ | |
| 50 and 100 μM | ↓proliferation | ||||
| UtLM | ~4 μM | ↑proliferation | [ | ||
| ↑PCNA, ↑cells in S phase | |||||
| >37 μM | ↓proliferation ↑apoptosis | ||||
| KS483, mouse bone marrow cells | 0.1–10.0 μM | ↑osteogenesis ↑ALP activity | [ | ||
| ↑nodule formation and calcium deposition | |||||
| >25 μM | ↓osteogenesis ↓ALP activity | ||||
| ↓nodule formation and calcium deposition | |||||
| KS483, mouse bone marrow cells | 0.1–1.0 μM | ↓adipocytes number | [ | ||
| 10–50 μM | ↓adipocytes number | ||||
| Glabrene isolated from | T47-D, MCF-7 | 100 nM–10 μM | ↑proliferation | [ | |
| >15 μM | ↓proliferation | ||||
| Glabridin | T-46D | 0.1–10 μM | ↑proliferation | [ | |
| >15 μM | ↓proliferation | ||||
| Isoliquiritigenin | MCF-7 | <1 μM | ↑proliferation | [ | |
| 10 μM | ↓proliferation | ||||
| Kaempherol | MCF-7 | <1 μM | ↑proliferation | [ | |
| >1 μM | ↓proliferation | ||||
| Quercetin | MCF-7 | <1 μM | ↑proliferation | [ | |
| >10 μM | ↓proliferation | ||||
| HCT-116 | 1–30 μM | ↑proliferation | [ | ||
| 40–100 μM | ↓proliferation | ||||
| HT-29 | 1–67 μM | ↑proliferation | |||
| 80–100 μM | ↓proliferation | ||||
| SCC-25 | 1–10 μM | ↑proliferation | [ | ||
| >100 μM | ↓proliferation | ||||
|
| |||||
| Isoliquiritigenin | HUVEC/PMA | <10 μM | ↑TIMP-2 | ↓JNK, p38 MAPK pathway | [ |
| 25 μM | ↓TIMP-2 | ||||
| Quercetin | RAW 264.7 | 10–100 nM | ↑PGE2 | [ | |
| 10–100 μM | ↓PGE2 | ||||
| basophils/fMLP | ~0.03–0.33 μM | ↑CD63, CD203c | [ | ||
| ~3–33 μM | ↓CD63, CD203c | ||||
| basophils/fMLP | 0.03–0.3 μM | ↑histamine | PI3K involvement | [ | |
| 33 μM | ↓histamine | ||||
|
| 100–200 μM | ↑lifespan | ↑ | [ | |
| 250 μM | ↓lifespan | ||||
| 0.006–0.01 mM | ↓mutagenicity | [ | |||
| 0.06–0.12 mM | ↑mutagenicity | ||||
| 0.1, 1 μM | ↑mutagenicity, CYP1A2 activity | [ | |||
| 50, 100 μM | ↓mutagenicity, CYP1A2 activity | ||||
* If the source of the compound was not specified it was obtained commercially; ↑ = increase, ↓ = decrease; 2-AAF—2-Acetylaminofluorene; AFB1—aflatoxin B1; ALP—alkaline phosphatase; CD203c—basophil-specific ectoenzyme E-NPP3; CD63—tetraspan transmembrane protein family; CYP1A2—Cytochrome P450 1A2; fMLP—bacterial formyl peptide N-formylmethionine-leucine-phenylalanine; HCT-116, HT-29—colon carcinoma cell line; HepG-2—human liver cancer cell line; HUVEC—human umbilical vein endothelial cell line; KS483—murine osteoprogenitor cell line; JNK—c-JUN terminal kinase; LC3-II—microtubule-associated protein 2 light chain 3; LoVo—human colon adenocarcinoma cell line; MCF-7—human breast adenocarcinoma cell line; MeIQ—2-amino-3, 4-dimethylimidazo [4,5-f]quinoline; MG-63—human osteoblast-like cells; MMP-9—matrix metallopeptidase 9; p53—tumor protein p53; PC-3—human prostatic carcinoma cell line; PCNA—proliferating cell nuclear antigen; PGE2—prostaglandin E2; PI3K—phosphoinositide-3 kinase; PMA—phorbol myristate acetate; RAW 264.7—murine macrophage cell line; p38 MAPK—p38 mitogen-activated protein kinase; SCC-25—oral squamous carcinoma cell line; T-47D—human breast cancer cell lines; TIMP-2—tissue inhibitor of metalloproteinase-2; UtLM—human uterine leiomyoma.
Figure 1Suggested mechanisms of biphasic concentration-dependent effects of phytoestrogens (on the basis of references cited in the review). ↑ = increase, ↓ = decrease; ER—estrogen receptor; ERK—extracellular signal-regulated kinase protein-serine/threonine kinase; MAPK—mitogen-activated protein kinase; MMP-9—matrix metallopeptidase 9; p53—tumor protein p53.
Biphasic concentration/dose-response relationship induced by resveratrol.
| Model | Concentration | Effects | Mechanism | Refs |
|---|---|---|---|---|
| NHEK | <50 μM | ↑viability | ↑CAT, Nrf2, KEAP1, NQO1, GCLC, GSR, G6PD, FOXO3, SIRT1, DAPK 1 (5–100 µM) | [ |
| 500 μM | ↓viability | ↓CAT, Nrf2, KEAP1, NQO1, GCLC, GSR, G6PD, FOXO3, SIRT1, DAPK1 150 µM | ||
| NHDF | 1–300 μM | ↑viability | ||
| 500 μM | ↓viability | |||
| HepG2 | 1–100 μM | ↑viability | ||
| 500 μM | ↓viability | |||
| NPCs | 1, 10, 20 μM | ↑proliferation | ↑ERK1/2, p38, p-CREB, Bcl-2, TrkA, synaptophysin, PSA-NCAM | [ |
| 50, 100 μM | ↓proliferation | ↓p-ERK1/2, p-p38 MAPK | ||
| ↑caspase-3 | ||||
| HT-29 | 1–10 μM | ↑proliferation | [ | |
| 50, 100 μM | ↓proliferation | ↑NADPH oxidase activity, ↑ɣH2AX, SIRT6 | ||
| Bovine spermatozoa | 1–50 μM | ↑viability | [ | |
| ↓superoxide anion production | ||||
| 100, 1000 μM | ↓viability | |||
| 100, 200 μM | ↑superoxide anion production | |||
| LNCaP | 5 μM, 10 μM | ↑DNA synthesis | ↓p21cip1, p27kip1 | [ |
| ↑Cdk2 activity | ||||
| ↑cyclins A, E | ||||
| >15 μM | ↓DNA synthesis | |||
| Rat ovarian | 10 μM | ↑DNA synthesis | [ | |
| granulosa cells | 30,50 μM | ↓DNA synthesis | ||
| Normal colon epithelial cells | 0.1–1 μM | ↓chromosomal instability, ↑viability | ↑ | [ |
| 100 μM | ↑chromosomal instability, ↓viability | ↓ | ||
| C12C12 | 10 μM | ↑cell motility | [ | |
| 40–60 μM | ↓cell motility | ↓miosin Tpe1 and total ATPase activity | ||
| HepG2 | 1, 10 μM | ↑apoM, | [ | |
| 100 μM | ↓apoM | |||
| hMSCs | 0.1 μM | ↓cellular senescence | ↑ | [ |
| 5, 10 μM | ↑cellular senescence | ↓ | ||
| ↑ | ||||
| HepG2/4NQO | 10, 25, 50 μM | ↓genotoxicity | [ | |
| 100, 250 μM | ↑genotoxicity | |||
| NK | 1.56, 3.13 μM | ↑cytotoxicity | ↑ | [ |
| ↑ | ||||
| 25, 50 μM | ↓cytotoxicity | |||
| HUVEC | 1 μM | ↓ROS | ↑ | [ |
| ↑viability, DNA synthesis | ↑PKC activity | |||
| 10, 50 μM | ↑ROS | ↓ | ||
| ↓viability, DNA synthesis | ↓PKC activity | |||
| Rats | 2.5 mg/kg | ↑aortic flow, LVDP, ↓infarct size | ↓cardiomyocyte apoptosis | [ |
| 25 mg/kg | ↓aortic flow, LVDP, ↑infarct size | ↑cardiomyocyte apoptosis | ||
| 100 mg/kg | no heart function | ↑cardiomyocyte apoptosis |
↑ = increase, ↓ = decrease; 4NQO—4-nitroquinoline-N-oxide; ɣH2AX—H2A histone family member X; apoM—apolipoprotein M; Bcl-2—B-cell lymphoma 2; C2C12—mouse myoblast cell line; CAT—catalase; Cdk—cyclin-dependent kinase; CREB—cAMP-response-element-binding protein; DAPK1—death-associated protein kinase 1; ERK1/2—extracellular signaling-regulated kinase; FOXO3—forkhead box O3; G6PD—glucose-6-phosphate dehydrogenase; GCLC—glutamate-cysteine ligase catalytic subunit; GSR—glutathione reductase; HepG2—human liver cancer cell line; hMSCs—human mesenchymal stem cell line; HT-29—colon carcinoma cell line; KEAP1—Kelch-like ECH-associated protein 1; LNCaP—androgen-sensitive human prostate adenocarcinoma cell line; LVDP—left ventricular developed pressure; NHDF—neonatal normal human dermal fibroblasts; NHEK—neonatal normal human epidermal keratinocytes; NK—human natural killer cells; NPCs—neural progenitor cells; NQO1—NAD(P)H dehydrogenase [quinone] 1; Nrf2—nuclear factor erythroid 2-related factor 2; ODC—ornithine decarboxylase; p21Cip1 cyclin-dependent kinase inhibitor 1; p27Kip1—cyclin-dependent kinase inhibitor 1B; PSA-NCAM—polysialylated neuronal cell adhesion molecule; p38—mitogen-activated protein kinase; PKC—protein kinase C; SAC—spindle assembly checkpoint; SIRT—sirtuin; SOX2—transcription factor (sex-determining region Y-box 2), TrkA—tropomyosin receptor kinase A. Resveratrol used in cited experiments was of commercial origin.
Phytochemicals exhibiting biphasic concentration/dose-responses.
| Compound * | Model | Concentration | Effect | Mechanism | Refs |
|---|---|---|---|---|---|
| Arctigenin | K-562 | ~27, 54 μM | ↑Mcl-1mRNA | [ | |
| ~107 μM | ↓Mcl-1mRNA | ||||
| Berberine | B16-F10, | 1.25–5.00 μM | ↑proliferation | ↑MAPK/ERK1/2 ↑PI3K/AKT | [ |
| MDA-MB-231, | 10–80 μM | ↓proliferation | |||
| MDA-MB-468, | |||||
| MCF-7, LS-174 | |||||
| PC-12 | 0.1–1.0 μM | ↑viability | ↑PI3K/AKT/Bcl-2 | [ | |
| 2–64 μM | ↓viability | ||||
| Caffeic acid | male F344 rats | 0.14% | ↓proliferation | ↓epithelial cells, S-phase cells | [ |
| 0.40, 1.64% | ↑proliferation | ↑epithelial cells, ↓S-phase cells in forestomach | |||
| (+) Catechin, rutin | 0.01–0.60 mM | ↓mutagenicity | [ | ||
| 1.2, 0.8 mM | ↑mutagenicity | ||||
| Cynarin | FSF-1, | 1–50 µM | ↑viability | ↑HO-1 activity | [ |
| 75–500 µM | ↓viability | ||||
| hTERT-MSC | 1–00 µM | ↑viability | ↑HO-1 activity | [ | |
| 75–500 µM | ↓viability | ||||
| EGCG |
| 50–300 µM | ↑lifespan | ↑ROS; ↑AMPK/SIRT1/FOXO | [ |
| 800–1000µM | ↓lifespan | ||||
| Falcarinol, Falcarindiol | primary myotube culture/H2O2 | 1.6–25.0 μM | ↑ROS production | ↑ | [ |
| 50, 100 μM | ↓ROS production | ↓ | |||
| Falcarindiol | primary | 0.61–9.80 nM | ↑viability | [ | |
| myotube culture | 2.5–5.0 μM | ↓viability | |||
| pBMEC | ~0.04–0.20 μM | ↑proliferation | [ | ||
| ~4–41 μM | ↓proliferation | ||||
| CaCo-2 | 1–10 μM | ↑proliferation | ↓caspase-3, DNA breakage | [ | |
| ↓apoptosis | |||||
| >20 μM | ↓proliferation | ↑caspase-3, DNA breakage | |||
| ↑apoptosis | |||||
| Glyceollin I |
| 10–100 nM | ↑CLS | [ | |
| >1 μM | ↓CLS | ||||
| Luteolin | MCF-7 | 1–10 μM | ↑viability | [ | |
| 30–1000 μM | ↓viability | ||||
| HepG2 | <35 μM | ↑LC3-II | [ | ||
| ~105 μM | ↓LC3-II | ||||
| 0.006 mM | ↑mutagenicity | [ | |||
| 1.2 mM | ↓mutagenicity | ||||
| Nanteine | synaptosomal membranes | 50 μM, 0.3 mM | ↑K+ -p-NPPase activity | [ | |
| >0.75 mM | ↓K+ -p-NPPase activity | ||||
| Naringenin |
| 200, 400 μM | ↑lifespan | ↑pupae formation | [ |
| 600, 800 μM | ↓lifespan | ↓pupae formation | |||
| Naphazarin |
| 50–500 μM | ↑lifespan | ↑skn-1 | [ |
| 1000 µM | ↓lifespan | ||||
| Panaxatriol saponins | PC-12 | 0.03–1.00 mg/ml | ↑proliferation | [ | |
| 4 mg/ml | ↓proliferation | ||||
| PC-12 /6-OHDA | 0.03–2.00 mg/ml | ↑viability | ↑PI3K/AKT/mTOR ↑AMPK/SIRT1/FOXO3 | ||
| 4 mg/ml | ↓viability | ||||
| Plumbagin |
| 1–45 μM | ↑lifespan | ↑skn-1 | [ |
| 100 μM | ↓lifespan | ||||
| Rosmarinic acid |
| 100–300 µM | ↑lifespan | ↑ | [ |
| 600 µM | ↓lifespan | ||||
| Rutin |
| 200, 400 μM | ↑lifespan | ↑longevity associated genes | [ |
| 600, 800 μM | ↓lifespan | ||||
| Salvianolic acid B | BMSCs | ~4–111 μM | ↑metabolic activity, ALP activity | [ | |
| ~223 μM | ↓metabolic activity, ALP activity | ||||
| Sulforaphane | T24, HepG2, Caco-2 | 1–5 μM | ↑proliferation | ↑RAS, RAF, MEK, ERK, PI3K, AKT and Nf-kB, FOXO Nrf2 pathways | [ |
| 10–40 μM | ↓proliferation | ||||
| T24 | 2.50, 3.75 μM | ↑migration | |||
| 5–40 μM | ↓migration | ||||
| HUVEC, PVC | 2.5–5.0 μM | ↑angiogenesis | ↑tube formation | ||
| 10, 20 μM | ↓angiogenesis | ↓tube formation | |||
| Isolated from | MSCs | 0.25, 1.00 μM | ↑proliferation | [ | |
| 20 μM | ↓proliferation | ||||
| <5 μM | ↓apoptotic cells | ||||
| 20 μM | ↑apoptotic cells | ||||
| 0.25, 1.00 μM | ↓senescence cells | ||||
| 5, 20 μM | ↑senescence cells | ||||
| 0.25 μM | ↓ROS production | ||||
| 20 μM | ↑ROS production | ||||
| Commercial source | MCF-7, HHL-5, HepG2, lymphoblastoid cells | <5 μM | ↑proliferation | [ | |
| >5 μM | ↓proliferation | ||||
| lymphoblastoid cells | 0.5–5.0 μM | ↑GSH | [ | ||
| 10 μM | ↓GSH | ||||
| Umbelliprenin | Jurkat T-CLL | 10, 25 μM | ↑apoptosis | [ | |
| 50, 100 μM | ↓apoptosis | ||||
| Z-ligustilide | PC-12/ OGD | 1–25 μM | ↑viability, ↓apoptosis | ↑HO-1 and Nrf2 translocation | [ |
| 50 μM | ↓viability, ↑apoptosis | ||||
| 0.1–0.5 mg/g diet | ↑GST, AChE, CYP, CES activities | ↑ | [ | ||
| 1, 5 mg/g diet | ↓GST, AChE, CYP activity | ↓ |
* If the source of the compound was not specified it was obtained commercially; ↑ = increase, ↓ = decrease; 2-AAF—2-Acetylaminofluorene; 6-OHDA—6-hydroxydopamine; AChE—acetylcholinesterase; AKT—protein kinase B; ALP—alkaline phosphatase; B16-F10—murine melanoma cell line; BMSCs—bone marrow-derived mesenchymal stem cells; CaCo-2—human colon cancer cell line; CES—carboxylesterase; CLS—chronologic life span; CYP—cytochrome P450; CYP4M14 (4S9)—cytochrome P450 4M14 (4S9); EGCG—epigallocatechin-3-gallate; FSF-1—human skin fibroblasts; GPx—glutathione peroxidase; GST—glutathione S-transferase; GSTS1—glutathione S transferase S1; HHL-5—human normal liver cell line; HO-1—heme oxygense 1; Hsp70—heat shock protein; HepG2—human liver cancer cell line; HUVEC—human umbilical vein endothelial cells; Jurkat T-CLL—Jurkat T-cell lymphocyte leukemia cells; K562—immortalized cell line derived from human leukemia; K+ -p-NPPase activity—K+ -p- nitrophenylphosphatase; LC3— microtubule-associated protein 1A/1B-light chain 3; LS-174—human colon cancer cell line; MDA-MB-231, MDA-MB-468, MCF-7MCF-7—human breast carcinoma cell lines; MSCs—mesenchymal stem cell line; OGD—oxygen-glucose deprivation; pBMEC—primary bovine mammary epithelial cells; PC-3—human prostatic carcinoma cell line; PC-12—phaeochromocytoma cell line; PI3K—phosphatidylinositol 3-kinase; PVC—pericytes; skn-1—cap’n’collar transcription factor; T24—bladder cancer cell line; hTERT-MSC—human normal telomerase-immortalized mesenchymal stem cells.
Figure 2Examples of mechanisms involved in the cellular response to low doses of phytochemicals–on the basis of findings presented in the current review. Phytochemicals can activate kinase cascades, including PKC, MAPK/ERK1/2, PI3K/AKT, which play a critical role in the regulation of cell growth, proliferation, survival, and apoptosis. Downstream effector of these kinases is transcription factor Nrf2, which is released from the complex with keap1 and translocates to the nucleus, binds to ARE and stimulates the expression of cytoprotective proteins, e.g., antioxidant enzymes and phase-2 proteins. SIRT-1 plays a key role in the cellular response to various stressors by activating transcription factor FOXO3, which induces genes encoding cytoprotective proteins. The transcriptional activity of FOXO3 is modulated by both AMPK and SIRT-1. PI3K/AKT is the major pathway mediating cell survival and inhibiting apoptosis. Bcl-2, a pro-survival, anti-apoptotic, and cytoprotective molecule, can be activated directly by chemicals or via PI3K/AKT pathway. AKT—serine/threonine protein kinase; AMPK—AMP-activated protein kinase; ARE—antioxidant response elements; Bcl2—B-cell lymphoma 2; ERK—extracellular signal-regulated kinase protein-serine/threonine kinase; FOXO3—forkhead box O3; KEAP1—Kelch-like ECH-associated protein 1; MAPK—mitogen-activated protein kinase; Nrf2—nuclear factor erythroid 2-related factor 2; PI3K—phosphatidylinositol 3-kinase; PKC—protein kinase C; SIRT1—sirtuin1.
Figure 3The percentage share of various types of experimental models applied in the reports cited in this review.